Breast Cancer

Bioscience company to manufacture genetic breast cancer risk-assessing reagents

Published in Women's Health Weekly, August 4th, 2005

Tm Bioscience Corporation (TMC), a provider of commercial genetic testing products, announced it has signed a 5-year agreement to supply custom Tag-It reagents to InterGenetics, Oklahoma City, Oklahoma, for OncoVue.

According to InterGenetics, Oncovue has been developed as the first genetic-based breast cancer risk test relevant to all women. The agreement anticipates InterGenetics will purchase a minimum of $7.5 million in reagents from Tm over the 5-year period. The agreement is contingent on Tm delivering Tag-It reagents which perform according to InterGenetics' specifications.

Breast cancer is one of the most frequently diagnosed cancers among...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (2005-08-04)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry